News Headlines Article

Experimental Huntington’s disease drug can be given less frequently
San Diego Union-Tribune

An experimental drug for Huntington’s disease from Carlsbad’s Ionis Pharmaceuticals appears to be more long-lasting than previously thought. If proven effective, the drug will become the first therapy that changes the course of the fatal genetic disease.

The drug will now be given once every two months by lumbar puncture instead of every month, said Ionis partner Roche. The Swiss drug company will sell the drug if it successfully completes clinical testing.